CHARITY COMMISSION
FOR ENGLAND AND WALES
Tru8toes' Annual Report for the period
From 1° January 2021
To
31 December 2021
Charity name: Salivary Gland Cancer UK
Charity registration number: 1182762
Objectives and Activities
Surnmary of th8 purposes of
the tharity as set out in ts
governing dooJm8nt
P¥• 1.17
Help those affected by rare salr¥ary gland
cancers.
AdvoGgte for thes8 patients and carers by
providing pe9r Support and infomation about
their disease, care and treatment.
Promote arKI assist r886ar¢h into all 88peci8
of 8alivary 918nd cancern, including caus08,
diagn￿18, tr8atmonl and cJJrn.
To educate the public in all thing8 related to
•alNary gland cancern, including raising
awarenoss of symptoms.
Summary of the main
activÉlie$ in relation to those
purposes for th8 public
benefit, in particular. the
activitios. projects or serrf1￿3
identrfied in the accwnts.
Pwa1.17•¥J
Supports'ng the communty via n person
and virtual meatings for patients, carers
and clinicians.
Providing
infomiation
via
leaflets,
meetings. the website and social media.
Raising awareness of these cancers and
their unmet need via speaking and
attending meetings and conference8.
Expanslon of the nfrtwo￿ to support
more salivary gland cancer type8.
Expansion of the chariVs outputs to
provide m(xe researGh and disease
speofic Yrformation.
Statemant confimiing
elher the trustees have
had regard to the guldance
i33uad by the Charity
Commission on public
b8n8frt
P￿1.18
The trustees have kopt in mnd tha charrty
Constrtution and Ihe guidance from the
Charities Commission in all of its, a¢tivrtie$.
The g0veM￿c￿ documents of tho Charrty
are rggularly rovièwad at Trust00 mgeting$.

Additional Inlorniation (Optional)
You ma choose to indude further statements where relevant atjout:
P•• 1.38
Policy on grant making
Pwa 1.JJ
Policy on social inv8Stm8nl
including program related
inv8Stm8nt
Pwn128
Contribution made by
volunteorn
(Xher
Achievements and Perforniance
SUppO￿n9 Ihe community in person
and virtU81 me8ling$ forpatients, carerts
8nd clini¢i8ns.
Summwy ofthe main
achiev•ments of the charity,
identrfying the diff¢r•n¢• th•
charty's work has made to
the circumstances of rts
beneficiaries and any wider
benefits to soa6ty as a
bthole.
120
For our hybrid (in por8Mlvti*ual> mootings
tarlier in the year we were able to support
bursaries for pats'ents and their carers to
support th￿r in person 8tt•ndanc6 when
needed.
Havng confidontly adapted to a vlrtual
environment during tho pandemic, w8 have
been able to continue to us8 Zoom to
accompany our in person meeting8. This h88
facilitated strong attendance from our
communty a(xoss
thè
country
and
Internat￿nally.
continued
to
provide
regular
communicalion and nowsletters to the
n8tsvork.
Our July 2021 meeting was focu$s•d on
'The challenges of diagnosis, and what this
means for treatments.. In Octobef 2021 our
hybrid gathering was trtled 'Understanding
Adenoid Cystic Carcinoma.. the rol8 of MYB..
Provit*ng infom78tion vi8 18allets,
meeb'n
s, the website and So￿81 media.

In January 2021 we launched on Instagram.
During the year we continued to develop the
online presence of the charity by providing
regular updato$ on our social media
platforms and the website to highlight news,
reports and key devebpments.
Raising awareness of these cancers and
their unmet need via speaking and
attendlng meetings and confernnces.
Dr Metcalf attended and spok8 at the
Amèrun Society of Clinical Oncology
('ASCO') 2021 Conference. He presented a
UK research study analysing the 'biobanked'
salNary gland cancer tumour DNA samples
from 120 patients was set up with the
support and input of Ihe SGC UK patient
nefv￿rk. (Clinical disease course and
survr¥al
(xrtcom88 following disease
recurrence in adenoid cystic carcinoma
{ACC) with NOTCH 8ignalling pathway
adNation. See reference in Journal of
Clinicol Oncology 202139.15 suppl, 6072-
6072).
Expansion of the nehvorf( to support
more salfvary gland cancer typ8S.
patients and clinicians.
Working at 8 European level with EURACAN
we havo been developing the ESMO
Guidelines for rare Salivary Gland Cancers,
and the STARTER registy. Both projects
h8va provided an opportunty for Europ8an-
WKle collaborat￿n and net4vork building
across 811 cancar types.
Exp•nsion of th charity'8 outyuts to
prowde morn research and dis88SO
swfic infom181ion.
Retuming to work after troatment for SGCS
can be dfficutt. The long-temi physic81
effects of treatments can make slmple tasks
at work. very challenging. We partnered
wrth Bristol Myers Squibb and the Head and
Neck ¢ommunrty to develop a Back-tovwork
Guide,. a ¢0•￿eated resource designed to
help people living with HNC get back to
As the ntterest in genomics gathers
momentum.
have started work on
educational material. n collaboration with
Roch•. lo h￿hlIght tho bon•frts of tumour
profiling to develop new, better and more
ta
eted treatments. The materials will

inform patiersts and also assist them in how
to donate tumours to the national salivary
gland cancer research pn)gramme at The
Christs'e cancer centre. Materials are duo to
be published li the first half of 2022.
W8 continued to woduce our VKleo $8riès,
releaS￿g recordings of the presentations at
our hybnd meetings to ensure we reach as
many people as possible.
Additlonal Infornjation (optlonal)
You ma
choose to include lurther statements where relevant about:
Achievements againsl
objecllve8 80t
Perfornianca of fundraising
activities against obiedives
Inve8tment perforniance
against objectives
1.41
Other

Financial Review
Review of th8 charit￿$
financial position 8t the end
of the period
Pm121
As at 31 Decembw 2021 the charity held
cash balance of £39,922, the result of
£13.314 in net receipts for the year.
The tharlty received income of £27.832. the
majonty being from donats'ons through
varnus sources induding donation pl8ffom)s
and personal 18gaciès, togeth8r with other
income received from cnllaborations with
other organi$8tion$.
The thariws financial position will allow
sufficient funding to 8upwI the initiatiV88
planned for 2022, &Trdude•J the charity's first
research grant
Statement explaining th8
policy for holding re8erve8
stating why they are hèld
p￿ 122
The cash balance is held in order to support
the overall objectives of the charity. Cash is
used to COV8r operating 8xpenses, dev8Sop
the charity's pr•s•nco through mart•ting
and fund 8pocrf•c patiorrtlclinician event8.
Amount of reserves held
Reason8 for hoksing zwo
res•rv•s
Details of fund materialty i)
dar￿11
Explanation of any
uncertainties about tho
charrty continuing as a going
Concern
Par8 122
Pw•122
£39,922 in cash.
Not applKablo
P•v• 124
Not applicablg
Pw*123
There arn no uncarta•)tio8 around the
charitys abilty lo (xxrtinue as a going
Additional infomiatlon {optlonal}
You ma
choose to indude further statsments where r818vant about..
Th8 ch8rW8 principal
sourc8s of funds (includina
any fundraising)
Pln 1.47
Investment policy and
obJeGtives including any
social investment policy
adopted
IA6
A de8¢ription of the principal
risks facing the tharty
P￿# 1.46
Oth8r

Structure. Governance and Management
Desuiptlon of charrtys
trusts..
Type of goveming documont
P¥a125
The chaiity 1$ gov8med by its Consttlution.
How is the d)arity
constituted?
' J unti1￿0[Pora1~
Pwa 125
The charity is a CIO.
..rinL.aF7nn r. i
Trust88 S818Ction melhods
Including details of any
constitutional provisions e.g.
election to post or name of
any person or body entitled
to appoint one or more
trust88S
Pva 125
Truste8s must be appThnted for a tenn of
three years by o resolution passed at a
properly convened m8eting of the charty
trustees.
en selecti)g trustees. the tharity tnjstees
hav8 regard to the skills, knovAedge and
oxperTence needed for thè •ffo¢tiv8
administration ofthe CIO.
Addltlonal Infomiatlon {optl¢>nal)
You ma choose to include further statemwts whor• rolovant about:
Policie8 and procedures
adopted for the induction and
training oftrustèès
p￿1.51
The charty's oryanisalional
structure and any W￿er
network with which thè
charity work6
Relationship with 8ny related
P8rt183
Other
Reference and Administrative details
name
Other name the cha
uses
Re
istered cha
number
S81iva
Gland C8nc8r UK
1182762

Charity's principal address
Intemational House. 24 Holborn Vbaduc*. London, EC1A 2BN

Names of the charfty trustso8 who manage th• charity
Dates •ct•d If not forwho
ar
TnMt¢e Mm•
oiric• (tl any)
Nam? of perdon lor body) entitted
oint tru8tè•
Iran
The Board
Emma Jane
Kinloch
Chair
Dr Robert Metcaff
Olorunkemi Fausat
Akanke 018iya
Shane Lisa Draper
Trust88
Treasurer
The Board
The Board
Chief Financial
Officer
The Board
10
12
13
14
15
16
17
18
19
orate trustees- nam08 of the direckns ai the date the re
Dlrgctor namo
wasa
roved
Name of trustees hoklirvJ trtle to property belong¥ig to the charity
Trn%teg nam•
Daw ad•tt If not for T*hol•

Funds held as custodian trustees on behalf of others
Description of the assèts
Not applicable
hekl in this ￿PaCty
Name and obieds of the
ch8rity on whose behalf the
assets are held and hiyw this
falls within the custodian
charitws objects
Not applubl8
Details of arrangements for
safe custody and
segregation of such assets
from the charity's own assets
Not appl&ibla
Additlonal inforniatlon lopffjonal)
Name8 and addro8898 of advl8ern (Optional Inforniatlon)
Typ• of
Nam•
Address
advl8er
Nam• of chl•f gx•cutlv• or nam08 of 8enlor •taff membern lQptlonal Inforniatlon)
Exemptions from disclosure
Reason for non41i8cktsure of ke
nnol delails
Other o
tional infonnation

Declarations
The tru$tee8 declare that thgy have approved the trustees. report •bov•.
Slgned on b•half of tho charlty's tru•te•s
Slgnature(s)
Full nam•(s)
Position (•g Secrotary,
Chalr. •te)
Emma Jane Kinloch
Shan8 Lisa Draper
Chair
Chief Financial Officer
Dats

Fok INfwiD ANDWALES
Recelos and paymerts accounts
CC18a
1%tJ
31str￿ur￿￿r2O1l
Soctioii A Rcceipis Jiid p2ytnent5
1olal
L•#Y¥r
ndt
41r•
lothll
*¥¢¢m•lorA
VJJ2
Tr•n*fw*

B6Liabrfth•
rkn*.Cha